Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis (NASDAQ: ACB) announces expansion of its recreational product portfolio with new offerings across Greybeard, San Rafael '71, and Tasty's brands. The new lineup includes Greybeard's Banana Gas Pure Live Resin Vape, Country Lemon Terp Slush, and Critical Diesel Pre-Rolls; San Rafael '71's 20 Pack Pre-Rolls; and Tasty's Diamond Infused Pre-Rolls in Mango, Honeydew, and Melon varieties, plus a Grape 510 Vape. These products focus on delivering premium, science-driven offerings with emphasis on flavor and intensity for Canadian cannabis consumers.
Aurora Cannabis reported strong fiscal Q2 2025 results with record adjusted EBITDA of $10.1 million, up 210% year-over-year. Total net revenue reached $81.1 million, a 29% increase driven by 41% growth in global medical cannabis and 21% growth in plant propagation. International revenue grew 93% to $35 million, exceeding Canadian Medical revenue for the first time. The company maintains a strong balance sheet with $152 million in cash and a debt-free cannabis business. Medical cannabis contributed 76% of consolidated net revenue with a 68% adjusted gross margin. The company reaffirms its target of positive free cash flow by December 31, 2024.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming second quarter 2025 earnings conference call scheduled for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time. The financial results will be released before market opening on the same day. Chairman and CEO Miguel Martin and CFO Simona King will host the conference call and Q&A session.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in partnership with MedReleaf Australia, has launched an enhanced range of premium medical cannabis oils in Australia. The new products include various cannabinoid ratios to meet diverse patient needs, such as Aurora THC 25 (Sativa and Indica), Aurora 12.5:12.5, Aurora 50:50, and Aurora 10:100 oils, all in 30mL bottles.
These oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, offering healthcare providers and patients a broader selection of treatment options. The expanded product portfolio demonstrates Aurora's commitment to advancing patient care through high-quality, science-driven cannabis solutions.
Key features of the new cannabis oil products include comprehensive cannabinoid profiles, high standards of quality and safety, and a broad selection for customized patient care. Healthcare professionals can contact MedReleaf Australia's clinical support team for additional information.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced a research collaboration with the University of British Columbia (UBC), funded by Genome British Columbia. The project, titled 'Genomics-enabled Aroma Breeding in Cannabis,' aims to validate genetic and chemical markers for fruity aroma in cannabis, a key consumer preference trait.
Led by Dr. Jose Celedon from Aurora and Professor Joerg Bohlmann from UBC, this research aligns with Aurora's breeding goals and will enhance its breeding program's accuracy and efficiency. The project will utilize Aurora's advanced cannabis genetic library and recent patents on fruity aroma markers. Aurora will contribute through sensory analysis and bioinformatic analyses, while UBC will focus on sequencing transcriptomes, analyzing volatile chemistry, and characterizing genes responsible for fruity aromas.
This collaboration demonstrates Aurora's commitment to innovation and scientific advancement in the cannabis sector, potentially impacting future product development and consumer satisfaction.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced significant changes to its Board leadership. CEO Miguel Martin has been appointed as Executive Chairman, while outgoing Chairman Ron Funk has been named Lead Independent Director. These appointments, effective immediately, were unanimously approved by Aurora's Board.
Martin, who has served as CEO since September 2020, will continue in this role while taking on additional responsibilities as Executive Chairman. The Board believes this combination of roles will promote strong leadership and efficient decision-making as Aurora aims for global growth.
In other Board changes, Michael Singer has been appointed to the Audit Committee and the Human Resource and Compensation Committee, while Rajesh Uttamchandani joins the HRCC and the Nominating & Corporate Governance Committee. These appointments are expected to bring valuable expertise to their respective committees.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has made significant advancements in auto-flowering research, potentially transforming cannabis cultivation in high-latitude regions. The company has received US Patent 12,002,546 for methods to determine photoperiod sensitivity in cannabis, enabling their breeding program to select for the auto-flowering trait.
This breakthrough could revolutionize outdoor cannabis cultivation, especially in regions like Canada. Aurora's research aims to enhance crop yield and adaptability by exploiting natural variations in cannabis' circadian rhythm. The company's breeding program has already yielded novel cultivars that produce 40-100% more flower than legacy varieties, significantly improving potency and yield while reducing cost per gram.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have launched the Luo CBD lozenge in Canada. This marks Vectura Fertin Pharma's first medical cannabis CBD product in the Canadian market. The lozenge, developed by Vectura Fertin Pharma, is manufactured by its subsidiary Cogent and distributed through Aurora's direct-to-patient e-commerce platform.
The collaboration aims to leverage Aurora's leading Canadian medical cannabis patient platform. The novel dissolvable format of the CBD lozenge offers easy dosing for patients. This launch follows the recent announcement of a commercial partnership between Cogent and Aurora, with plans to explore future medical cannabis product launches in Canada.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) held its Annual General and Special Meeting on August 9, 2024, with 27.23% of issued and outstanding shares represented. All proposed matters were approved by shareholders, including the election of directors, appointment of Ernst & Young LLP as auditors, amendments to various compensation plans, renewal of the Shareholder Rights Plan, and a non-binding advisory resolution on executive compensation.
Notable voting results for director elections include Miguel Martin with 93.29% votes FOR, Chitwant Kohli with 92.37% votes FOR, and Norma Beauchamp with 89.47% votes FOR. The lowest approval was for Ron Funk, receiving 79.26% votes FOR.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced its Q1 fiscal 2025 results, highlighting positive free cash flow of $6.5 million and a 12% year-over-year increase in total quarterly net revenue to $83.4 million. The company achieved record net revenue of $47.2 million in global medical cannabis and generated Adjusted EBITDA of $4.9 million, an 87% YoY increase. Aurora ended the quarter with a debt-free cannabis business and a cash position of ~$182 million. The company's performance was driven by strong growth in the global medical cannabis segment and a record contribution from its Bevo plant propagation business. Aurora's CEO, Miguel Martin, emphasized the company's commitment to operational excellence and strategic growth, positioning it well for sustained positive momentum.
FAQ
What is the current stock price of Aurora Cannabis Common Shares (ACB)?
What is the market cap of Aurora Cannabis Common Shares (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
